Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPM8 | Q7Z2W7 | 3/20 | 0.35 |
| ▸ | CRHR1 | P34998 | 2/20 | 0.33 |
| ▸ | CHRNA7 | P36544 | 2/20 | 0.31 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.30 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL964427 | 0.93 | TRPM8 (0.32) | TRPM8CRHR1CHRNA7NR3C1 | |
| SCHEMBL966059 | 0.88 | IRAK4 (0.35) | CRHR1 | |
| SCHEMBL963320 | 0.88 | TRPM8 (0.33) | TRPM8CRHR1POLB | |
| SCHEMBL964579 | 0.88 | TRPM8 (0.33) | TRPM8POLB | |
| SCHEMBL961670 | 0.87 | POLB (0.34) | TRPM8CRHR1POLB | |
| SCHEMBL966246 | 0.86 | POLB (0.33) | TRPM8POLB | |
| SCHEMBL5119940 | 0.81 | NR3C1 (0.34) | TRPM8CHRNA7POLBNR3C1 | |
| SCHEMBL965516 | 0.81 | CHRNA7 (0.33) | CRHR1CHRNA7POLBNR3C1 | |
| SCHEMBL962680 | 0.80 | ALDH1A1 (0.33) | POLBNR3C1 | |
| SCHEMBL964464 | 0.79 | NPY5R (0.35) | CRHR1PTGDR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110009384-A1 | FUSED RING COMPOUNDS AS PARTIAL AGONISTS OF PPAR-GAMMA | TAKEDA PHARMACEUTICAL COMPANY LIMITED | 2011-01-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110009384-A1 | FUSED RING COMPOUNDS AS PARTIAL AGONISTS OF PPAR-GAMMA | PPARA, PPARD, PPARG | TRPM8 1651/4885CRHR1 780/4885CHRNA7 790/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.